GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease

Completed · Phase 2

Conditions studied: Alzheimer Disease

In brief

A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease

Key facts

Study ID

NCT00414622

Run by

CoMentis

People needed

60

Starts

2006-11-01

Expected to finish

2007-04-01

Last updated by the study team

2007-04-19

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• probable Alzheimer

You may not qualify if…

• others

Where it is running

• Clinical Dept. — 280 South San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.